Subrot Sarma DOWNLOAD PDF
Introduction: SARS-CoV-2 virus is responsible for inflicting COVID-19 pandemic. Considering virulence towards health & its economic effect on the population, suitable drug developmental strategy should be devised. An evaluation is provided here in the form of minireview dissecting the available therapeutic strategies, drugs and their mode of action against ssRNA+ viral infection including SARS-CoV-2 virus. The aim turned into to enlist the call of the antiviral agents and mechanisms associated with a viral life cycle that may be exploited probably to be used as therapeutic means to neutralize the SARS-CoV-2 viral infection. Methods: Using an online database like PubMed, MEDLINE, Embase, Google scholar, a systematic literature search was performed following key-word: antiviral agents, inhibitor ss RNA+, mechanism of antiviral activity, SARS-CoV-2, viral life-cycle, In silico/In vivo/In vitro. Results: The data identified and highlighted in the present assessment could be used for developing a novel therapeutic strategy against SARS-CoV-2 that can be categorized into 3 clusters. Cluster I- unique (for SARS-CoV-2) endocytic antiviral mechanism as potential drug target that may be exploited for drug design using both computational and In vivo approach. Cluster II- a total of 7 medicaments is hypothesized to act as an antiviral agent against SARS-CoV-2 affecting multiple steps of viral entry and endocytosis. Molecular simulation and In vivo analysis of the compounds are put forward for further analysis. Cluster III- a total of 21 physic used as an antiviral drug against SARS-CoV-2 in the In-silico setup calls for In vivo and In vitro analysis. Miscellaneous- Computational and In vivo investigation against SARS- CoV-2 viral infection using novel targets of CD147, Vimentin as an antiviral strategy. Novelty – CAR-TV- (chimeric antigen receptor -T cell-virus) therapy against SARS-CoV-2 virus is predicted with its potential receptor blueprint. Conclusion: Antiviral drug targets and therapeutic agents examined against ssRNA+ virus should get the priority to design medicine (In silico, In vivo, In vitro) against SARS-CoV-2. Novel draft of CAR-TV cell therapy with its proposed design of the receptor/antibody has the potential to be used as an effective drug development strategy against SARS-CoV-2 viral infection including any antimicrobial infection showing unique antigenic characteristics.
Keywords: ssRNA+, RNA dependent RNA polymerase, Endocytosis, Molecular simulation, CAR-T